Across TCGA pan-cancer cohorts, STYXL2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of STYXL2’s most consistent transcriptional readouts.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where STYXL2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types STYXL2 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.
PDAC and CCRCC are the cancer types where STYXL2 tumor–normal differential expression is most reproducible.